InnSight Technology, a Pittsburgh-based medical device firm, has secured a $515,000 investment from the Richard King Mellon Foundation. The funding, awarded after the company won a pitch competition, will accelerate the development of its OcuCheck™ technology. This device uses tear fluid analysis for point-of-care diagnostics to improve early disease detection.
Advancing Point-of-Care Diagnostics
The investment results from InnSight earning first place in the foundation's Social Impact Investment Pitch Competition. These funds will advance the OcuCheck™ platform through critical engineering, manufacturing, and clinical validation stages. This support is crucial as the company moves its technology toward commercialization.
The OcuCheck™ system is a multiplex electrochemical tear fluid sensor designed for point-of-care use. It rapidly measures multiple biomarkers from a small tear sample, delivering quantitative results within minutes. This allows objective data to be integrated directly into a routine eye examination.
While its applications are broad, the technology is initially being developed to diagnose dry eye disease. If cleared by the FDA, it would be the only device capable of simultaneously quantifying both MMP-9 and tear fluid osmolarity. This dual measurement provides clinicians with a more complete diagnostic picture.
A New Frontier in Diabetes Detection
InnSight's vision extends beyond ophthalmology, focusing on the early diagnosis and prediction of diabetes. As a leading cause of vision loss, diabetes requires better screening methods. The company aims to transform millions of annual diabetic eye exams into proactive health screenings.
This approach holds promise for rural and underserved communities where access to primary care is often limited. For many, an eye exam is one of their few consistent healthcare interactions. Integrating tear analysis into these visits could lead to earlier detection and intervention for at-risk patients.
CEO Leanne Labriola emphasized the technology's potential to improve lives by expanding the role of routine eye care. She stated the company envisions a future where these exams help identify diseases like diabetes much sooner. This proactive model aims to enhance clinical intervention and improve patient outcomes.
Bolstering Pittsburgh's Life Sciences Hub
The investment also underscores Pittsburgh's growing reputation as a center for life sciences innovation. Labriola noted that support from a prestigious local institution like the Richard King Mellon Foundation is vital. It helps translate research into tangible technologies that can significantly improve public health.
The funding comes from the foundation's Social-Impact Investment Program, which supports for-profit startups with missions aligned to its philanthropic strategy. The foundation has invested over $32 million across 78 different impact-focused companies. This program is a key part of its strategy to foster social change.
It is important to note that the OcuCheck™ device is currently in development and has not yet been cleared by the FDA. The company is actively working through the necessary validation and regulatory processes. This investment will be instrumental in navigating these final steps toward market entry.
The $515,000 investment from the Richard King Mellon Foundation marks a significant milestone for InnSight Technology. It accelerates the development of the OcuCheck™ platform and validates its potential to revolutionize diagnostics. This funding strengthens Pittsburgh's innovation ecosystem while paving the way for improved patient care globally.